BlackRock
CLPT icon

BlackRock’s ClearPoint Neuro CLPT Stock Holding History

BlackRock’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.5M Buy
2,379,804
+297,054
+14% +$3.71M ﹤0.01% 2772
2026
Q1 		$19M Buy
2,082,750
+39,117
+2% +$494K ﹤0.01% 3120
2025
Q4 		$28M Buy
2,043,633
+181,887
+10% +$3.37M ﹤0.01% 2893
2025
Q3 		$40.6M Buy
1,861,746
+127,595
+7% +$1.5M ﹤0.01% 2632
2025
Q2 		$20.7M Buy
1,734,151
+1,323,026
+322% +$16.7M ﹤0.01% 3004
2025
Q1 		$4.89M Buy
411,125
+17,862
+5% +$278K ﹤0.01% 3659
2024
Q4 		$6.05M Buy
393,263
+21,662
+6% +$281K ﹤0.01% 3645
2024
Q3 		$4.17M Buy
371,601
+5,203
+1% +$49.8K ﹤0.01% 3771
2024
Q2 		$1.97M Sell
366,398
-1,107,575
-75% -$6.41M ﹤0.01% 3970
2024
Q1 		$10M Buy
1,473,973
+3,917
+0.3% +$27.4K ﹤0.01% 3350
2023
Q4 		$9.98M Buy
1,470,056
+105,822
+8% +$599K ﹤0.01% 3399
2023
Q3 		$6.83M Sell
1,364,234
-9,542
-0.7% -$56.8K ﹤0.01% 3527
2023
Q2 		$9.95M Buy
1,373,776
+962,892
+234% +$8.19M ﹤0.01% 3422
2023
Q1 		$3.47M Sell
410,884
-1,858
-0.5% -$16.3K ﹤0.01% 3798
2022
Q4 		$3.5M Sell
412,742
-78
-0% -$739 ﹤0.01% 3889
2022
Q3 		$4.28M Buy
412,820
+115,127
+39% +$1.52M ﹤0.01% 3819
2022
Q2 		$3.88M Sell
297,693
-872,160
-75% -$8.91M ﹤0.01% 3939
2022
Q1 		$12.2M Sell
1,169,853
-6,502
-0.6% -$59.2K ﹤0.01% 3472
2021
Q4 		$13.2M Buy
1,176,355
+12,783
+1% +$191K ﹤0.01% 3509
2021
Q3 		$20.7M Buy
1,163,572
+14,362
+1% +$269K ﹤0.01% 3251
2021
Q2 		$21.9M Buy
1,149,210
+829,123
+259% +$16M ﹤0.01% 3238
2021
Q1 		$6.77M Buy
320,087
+272,022
+566% +$5.82M ﹤0.01% 3799
2020
Q4 		$763K Sell
48,065
-1,335
-3% -$12K ﹤0.01% 4276
2020
Q3 		$270K Sell
49,400
-472
-0.9% -$2.08K ﹤0.01% 4354
2020
Q2 		$177K Buy
49,872
+41,529
+498% +$154K ﹤0.01% 4389
2020
Q1 		$30K Buy
8,343
+570
+7% +$2.8K ﹤0.01% 4554
2019
Q4 		$37K Buy
+7,773
New +$32.2K ﹤0.01% 4576

Other funds holding CLPT

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
CFM
Compass Financial Management Tampa, Florida $829M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock's CLPT Position: Q2 2026 in Review

BlackRock increased its ClearPoint Neuro (CLPT) stake by 14% in Q2 2026, buying an estimated $3.71M and bringing the position to 2,379,804 shares worth $42.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2772.

BlackRock first reported a position in CLPT in Q4 2019 and has held it in 27 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • BlackRock held 2,379,804 shares of ClearPoint Neuro worth $42.5M as of Q2 2026.
  • BlackRock bought 297,054 ClearPoint Neuro shares in Q2 2026, an estimated $3.71M.
  • ClearPoint Neuro made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2772 holding.
  • BlackRock first reported a position in ClearPoint Neuro in Q4 2019 and has held it in 27 quarters since.
  • 129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.